Index of /SERVIER/AML/SVR-AML-TIB-003250-1 (8.13.24, 11.44 AM)/
../
1.0-Efficacy-OS/ 13-Aug-2024 15:54 -
10.0-Safety/ 13-Aug-2024 16:11 -
11.0-Dosing/ 13-Aug-2024 16:12 -
12.0-IDH1/ 13-Aug-2024 16:13 -
12.1-IDH1-MOA/ 13-Aug-2024 16:13 -
13.0-NCCN/ 13-Aug-2024 16:13 -
2.0-Efficacy-CR_CRh/ 13-Aug-2024 15:54 -
2.1-Duration-of-response/ 13-Aug-2024 15:54 -
2.2-Time-to-response/ 13-Aug-2024 15:54 -
2.3-Hematologic-parameters/ 13-Aug-2024 15:55 -
2.5-Safety/ 13-Aug-2024 15:56 -
3.0-Efficacy-CR-and_or-CRh/ 13-Aug-2024 15:56 -
3.1-Duration-of-response/ 13-Aug-2024 15:57 -
3.2-Time-to-response/ 13-Aug-2024 15:58 -
3.3-Transfusion-independence/ 13-Aug-2024 15:59 -
3.4-OS/ 13-Aug-2024 15:59 -
3.5-Hematologic-parameters/ 13-Aug-2024 16:00 -
3.6-Safety/ 13-Aug-2024 16:01 -
4.0-Dosing-regimen/ 13-Aug-2024 16:02 -
4.1-Dosing-guidance/ 13-Aug-2024 16:02 -
5.0-IDH1/ 13-Aug-2024 16:03 -
5.1-TESTING/ 13-Aug-2024 16:04 -
5.2-MoA/ 13-Aug-2024 16:05 -
6.0-GUIDELINES/ 13-Aug-2024 16:05 -
7.0-INDICATIONS-SUMMARY/ 13-Aug-2024 16:06 -
8.0-Home/ 13-Aug-2024 16:07 -
9.0-Efficacy-UNMET_NEED/ 13-Aug-2024 16:07 -
9.1-Efficacy-REMISSION/ 13-Aug-2024 16:08 -
9.2-Efficacy-TRANSFUSION_INDEPENDENCE/ 13-Aug-2024 16:09 -
9.3-Efficacy-TIME_TO_RESPONSE/ 13-Aug-2024 16:10 -
9.4-Efficacy-OVERALL_SURVIVAL/ 13-Aug-2024 16:11 -